Phase i study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer

International Journal of Clinical Oncology

Volumn 17, Issue 2, 2012, Pages 150-154

  Kambe, Mariko ^a   Kikuchi, Hiroaki ^b   Gamo, Makio ^c   Yoshioka, Takashi ^d   Ohashi, Yasuo ^e   Kanamaru, Ryunosuke ^f  

^a Senseki Hospital   (Japan)

^b South Miyagi Medical Center   (Japan)

^c Osaki Citizen Hospital   (Japan)

^d YAMAGATA UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f Naikakawaramachi Hospital   (Japan)

Author keywords

5 Fluorouracil (5 FU); Colorectal cancer; Irinotecan (CPT 11)

Indexed keywords

FIRTECAN; FLUOROURACIL; IRINOTECAN;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; COLORECTAL CANCER; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MAXIMUM TOLERATED DOSE; METASTATIC COLORECTAL CANCER; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA;

EID: 84862856658     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0272-9     Document Type: Article

References (14)

1. Kawato Y, Aonuma M, Hirota Y et al (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4191
2. Sylvie G, Daniel C, Isabelle H et al (1997) Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer 73:729-734
3. Loffler TM, Drogen C, Hausamen TU (1999) Weekly 24-hours infusion irinotecan (CPT-11) in 5-FU pretreated metastatic colorectal cancer. Proc Am Soc Clin Oncol 18:240a (abstract 922)
4. Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluoro-uracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914
5. Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer: a multicenter randomised trial. Lancet 355:1041-1047
6. Gerrits CHJ, Jonge MJA, Schellens JHM et al (1997) Topoiso-merase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer 76:952-962
7. Sadahiro S, Suzuki T, Maeda Y et al (2009) Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer. Oncology 76(5):338-341
8. Sadahiro S, Suzuki T, Maeda Y et al (2008) Phase I/II study of 24 hour infusion of irinotecan combined with oral UFT for meta-static colorectal cancer. Chemotherapy 54:140-146
9. Abeloff MD, Slavic M, Luc GD et al (1984) Phase I trial and pharmacokinetic studies of alpha difluoromethylornithine-an inhibitor of polyamine biosynthesis. J Clin Oncol 2:124-130
10. Grothey A, Sargent D, Goldberg RM et al (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22(7):1209-1214
11. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. Colon cancer-v.3.2011. http://www.nccn.org/professionals/physician- gls/PDF/colon.pdf
12. Ohtsu A, Boku N, Yoshioka T et al (2003) A phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703). Jpn J Clin Oncol 33(1): 28-32
13. Muro K, Boku N, Shimada Y et al (2010) Irinotecan plus S-1(IRIS) versus fluorouracil and folinic acid plus irinotec-an(FOLFIRI) as second-line chemotherapy for metastatic colo-rectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11(9):853-860
14. Okuyama N, Hazama S, Nozawa H et al (4) Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1*28/*6 polymorphisms. Jpn J Clin Oncol 41:477-482